Loading...
01/11 04:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: strong YUPELRI sales growth and potential milestone payments are positive, but financial risks and supply chain challenges could dampen enthusiasm. The Q&A section reveals some uncertainty about hospital performance and regulatory timelines, which tempers optimism. Despite the company's commitment to shareholder returns, the lack of clear guidance on certain issues and typical seasonality concerns suggest a cautious market reaction, leading to a neutral sentiment.
YUPELRI net sales $66.7 million, up 10% year-over-year, driven by a 9% increase in demand and favorable pricing due to improved channel mix.
Hospital doses for YUPELRI Up 49% year-over-year, indicating strong hospital performance and effectiveness of the selling strategy.
Full year YUPELRI sales $239 million, up 8% year-over-year, with an 11% growth in demand.
TRELEGY full year sales $3.5 billion, up 26% year-over-year, triggering a $50 million milestone payment.
Collaboration revenue Approximately $19 million, up 8% year-over-year.
Operating expenses (excluding share-based compensation) $22 million, increased due to commercial and medical affairs spend and increased R&D expenses.
Cash utilized in Q4 $3 million, with a total cash burn of $14 million for the full year.
Cash at year-end $88 million, excluding the $50 million TRELEGY milestone cash receipt.
Share-based compensation expense Expected to decrease year-over-year to a range of $18 million to $20 million.
Non-GAAP losses Expected to be similar to 2024 levels, with non-GAAP losses of $16 million.
SG&A expense (excluding share-based compensation) Expected to be between $50 million and $60 million for the year.
YUPELRI Net Sales: Fourth quarter YUPELRI net sales increased 10% over the fourth quarter of 2023, reaching $66.7 million, an all-time high.
Ampreloxetine Development: Solid enrollment in CYPRESS throughout the quarter; positive exchange with the FDA reaffirmed expectations around filing.
TRELEGY Milestone Payment: Earned a $50 million milestone payment from Royalty Pharma based on 2024 TRELEGY net sales reported by GSK.
Ampreloxetine Market Research: Market research underscores the potential for ampreloxetine to address significant unmet needs of patients with MSA and symptomatic nOH.
YUPELRI Market Share: Achieved nearly 20% long-acting Neb market share by the end of Q4.
TRELEGY Future Milestones: Potential for an additional $150 million of milestones in the coming 24 months.
Ampreloxetine Target Market: Ampreloxetine could address the high unmet need in the nOH population if FDA approved, with 90% of neurologists likely to prescribe.
Hospital Performance: Hospital performance was excellent with doses up 49% year-over-year.
Expense Management: Continued strong expense management and capital discipline to deliver sustainable value.
Cash Position: Ended the year with $88 million of cash, excluding the $50 million TRELEGY milestone cash receipt.
Strategic Priorities for YUPELRI: Focus on growing revenue while increasing brand profitability; potential for a near-term $25 million sales milestone in the U.S.
Ampreloxetine NDA Filing: Preparing for an expedited NDA filing and requesting priority review.
TRELEGY Royalties: Expect to receive several hundred million of cumulative royalties starting in 2029.
Regulatory Risks: The company discussed the potential risks associated with the regulatory approval process for ampreloxetine, particularly the need for a positive outcome from the CYPRESS study to support an expedited NDA filing.
Market Competition: There is a significant competitive pressure in the market for nOH therapies, as indicated by the high unmet need for improved treatments, which could impact the market share and sales potential of ampreloxetine.
Financial Risks: The company highlighted the impact of typical seasonality on YUPELRI sales, which could affect revenue in the first quarter of 2025, as well as the accounting treatment for TRELEGY milestones that may limit recognized income.
Supply Chain Challenges: While not explicitly stated, the discussion around the growth in hospital settings and demand generation implies potential supply chain challenges in meeting increased demand for YUPELRI.
Economic Factors: The overall economic environment and its impact on healthcare spending could pose risks to the company's revenue growth and profitability.
YUPELRI Revenue Growth: Focus on growing revenue while increasing brand profitability, with a potential near-term $25 million sales milestone in the U.S. and milestone and royalty income from China once approved.
Ampreloxetine Development: Completing enrollment in the CYPRESS study and preparing for an expedited NDA filing, with plans to request priority review.
TRELEGY Milestones: Potential for an additional $150 million in milestones over the next 24 months, alongside retained interest in TRELEGY royalties.
Expense Management: Commitment to strong expense management and capital discipline to deliver sustainable value to investors.
2025 R&D Expense Guidance: Guiding R&D expense (excluding share-based comp) between $32 million and $38 million.
2025 SG&A Expense Guidance: Expecting SG&A expense (excluding share-based comp) to be between $50 million and $60 million.
2025 Share-Based Compensation Guidance: Expecting share-based comp to decrease to a range of $18 million to $20 million.
2025 Non-GAAP Losses and Cash Burn: Expecting non-GAAP losses and cash burn to be similar to 2024 levels, with higher levels in the first half of the year and improvements in the second half.
TRELEGY Milestone Accounting: Only recognizing other income if cumulative milestones exceed $194 million, impacting income recognition in 2026.
TRELEGY Milestone Payments: Theravance expects to receive up to $150 million in potential milestones related to TRELEGY over the next 24 months.
Cash Position: The company ended the year with $88 million in cash, excluding a recent $50 million milestone payment from Royalty Pharma.
Shareholder Return Commitment: Theravance is committed to returning excess capital to shareholders and ensuring they benefit from the company's financial success.
The earnings call highlighted strong financial performance with YUPELRI's sales growth and a robust cash position. The company's strategic focus on the CYPRESS study and potential ampreloxetine launch is promising, despite some regulatory risks. The Q&A revealed confidence in study design and operational execution, with analysts showing interest in future capital returns and pipeline evaluations. Overall, the positive financial metrics, strategic milestones, and optimistic outlook outweigh the risks, suggesting a positive stock price movement.
The earnings call summary indicates strong financial performance, with significant growth in hospital volume, collaboration revenue, and a solid cash position. The Q&A section reveals management's strategic focus on improving YUPELRI's channel mix and addressing payer perspectives for ampreloxetine. Despite some uncertainties in the timeline and pricing, overall sentiment remains positive due to strong revenue growth and financial health. The lack of market cap data suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
The earnings call presents a mixed picture: strong YUPELRI sales growth and potential milestone payments are positive, but financial risks and supply chain challenges could dampen enthusiasm. The Q&A section reveals some uncertainty about hospital performance and regulatory timelines, which tempers optimism. Despite the company's commitment to shareholder returns, the lack of clear guidance on certain issues and typical seasonality concerns suggest a cautious market reaction, leading to a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
